Sexual Harassment in the City of Sin : Windsor, Ontario, 1965-1980

https://scholar.uwindsor.ca/undergraduate-major-papers/1009/thumbnail.jp

Case 9 : Shifting Culture Between Patients and Health Care Teams To Impact Symptom Screen and Management

Health Promotion Specialist Lisa Grey is faced with the task of strengthening patient and health care team culture using the Edmonton Symptoms Assessment Screening (ESAS) tool. ESAS is a standardized symptom screening tool used in health care settings across Ontario and is completed by patients at each clinic visit. The tool measures and tracks a patient’s symptom severity relating to nine common cancer symptoms. Symptoms are an indication of the progression of cancer and patient health status. ESAS gives an opportunity to identify symptoms earlier on, prevent emergency admission, and manage symptoms such as pain (Barbera et al., 2012; Barbera et al., 2015). The percentage of total cancer patients who were screened at least once with ESAS had declined at the London Regional Cancer Program; screening rates were below the provincial target of 70% and the provincial average of 58.4% (Cancer Care Ontario, 2014). Grey oversees five work streams in an effort to change attitudes and beliefs among patients and health care employees, and highlight the value of using ESAS on a consistent basis

HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors

Since the human immunodeficiency virus (HIV) was discovered as the etiological agent of acquired immunodeficiency syndrome (AIDS), it has encouraged much research into antiviral compounds. The reverse transcriptase (RT) of HIV has been a main target for antiviral drugs. However, all drugs developed so far inhibit the polymerase function of the enzyme, while none of the approved antiviral agents inhibit specifically the necessary ribonuclease H (RNase H) function of RT. This review provides a background on structure-function relationships of HIV-1 RNase H, as well as an outline of current attempts to develop novel, potent chemotherapeutics against a difficult drug target

HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors

Since the human immunodeficiency virus (HIV) was discovered as the etiological agent of acquired immunodeficiency syndrome (AIDS), it has encouraged much research into antiviral compounds. The reverse transcriptase (RT) of HIV has been a main target for antiviral drugs. However, all drugs developed so far inhibit the polymerase function of the enzyme, while none of the approved antiviral agents inhibit specifically the necessary ribonuclease H (RNase H) function of RT. This review provides a background on structure-function relationships of HIV-1 RNase H, as well as an outline of current attempts to develop novel, potent chemotherapeutics against a difficult drug target